NXP800 activates the unfolded protein response, altering AR and E2F function to impact castration-resistant prostate cancer growth.
Welti J, Bogdan D, Figueiredo I, Coleman I, Jiménez Vacas J, Liodaki K, Weigl F, Buroni L, Zeng W, Bernett I, Bertan C, Roumeliotis TI, Bhamra A, Rekowski J, Gurel B, Neeb AJ, Ning J, Li D, Gil VS, Riisnaes R, Miranda S, Crespo M, Ferreira A, Tunariu N, Pasqua E, Chessum N, Cheeseman M, Te Poele R, Powers M, Carreira S, Choudhary J, Clarke P, Banerji U, Swain A, Jones K, Yuan W, Workman P, Nelson PS, de Bono JS, Sharp A.
Welti J, et al. Among authors: li d.
Clin Cancer Res. 2025 Jan 9. doi: 10.1158/1078-0432.CCR-24-2386. Online ahead of print.
Clin Cancer Res. 2025.
PMID: 39787247